US10085983, Compound AZD-9291 US20230322822, Compound AZD9291 BDBM50029668 AZD-9291 Osimertinib WO2022090481, Example osimertinib US11111233, Example AZD9291 US11896597, Compound AZD9291 US9890168, Compound AZD-9291 US10227342, Example 24
- Gao, H; Yang, Z; Yang, X; Rao, Y Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors. Bioorg Med Chem 25: 4553-4559 (2017)
- Grabe, T; Jeyakumar, K; Niggenaber, J; Schulz, T; Koska, S; Kleinbölting, S; Beck, ME; Müller, MP; Rauh, D Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines. ACS Med Chem Lett 14: 591-598 (2023)
- Ding, S; Gao, Z; Hu, Z; Qi, R; Zheng, X; Dong, X; Zhang, M; Shen, J; Long, T; Zhu, Y; Tian, L; Song, W; Liu, R; Li, Y; Sun, J; Duan, W; Liu, J; Chen, Y Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors. Eur J Med Chem 238: (2022)
- Zhou, P; Chen, G; Gao, M; Wu, J Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC. Bioorg Med Chem 26: 6135-6145 (2018)
- Dong, H; Ye, X; Zhu, Y; Shen, H; Shen, H; Chen, W; Ji, M; Zheng, M; Wang, K; Cai, Z; Sun, H; Xiao, Y; Yang, P Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC. J Med Chem 66: 6849-6868 (2023)
- Shaikh, M; Shinde, Y; Pawara, R; Noolvi, M; Surana, S; Ahmad, I; Patel, H Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. J Med Chem 65: 1008-1046 (2022)
- Wu, T; Yu, B; Xu, Y; Du, Z; Zhang, Z; Wang, Y; Chen, H; Zhang, LA; Chen, R; Ma, F; Gong, W; Yu, S; Qiu, Z; Wu, H; Xu, X; Wang, J; Li, Z; Bian, J Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer. J Med Chem 66: 15340-15361 (2023)
- Xu, F; Zhang, X; Chen, Z; He, S; Guo, J; Yu, L; Wang, Y; Hou, C; Ai-Furas, H; Zheng, Z; Smaill, JB; Patterson, AV; Zhang, ZM; Chen, L; Ren, X; Ding, K Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells. J Med Chem 65: 14032-14048 (2022)
- Obst-Sander, U; Ricci, A; Kuhn, B; Friess, T; Koldewey, P; Kuglstatter, A; Hewings, D; Goergler, A; Steiner, S; Rueher, D; Imhoff, MP; Raschetti, N; Marty, HP; Dietzig, A; Rynn, C; Ehler, A; Burger, D; Kornacker, M; Schaffland, JP; Herting, F; Pao, W; Bischoff, JR; Martoglio, B; Alice Nagel, Y; Jaeschke, G Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. J Med Chem 65: 13052-13073 (2022)
- Liu, Q; Luo, Y; Li, Z; Chen, C; Fang, L Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity. Bioorg Med Chem 36: (2021)